Bart Heeg

Vice President, HEOR Global

Bart has been leading and conducting ​Health Economic and Outcomes Research (HEOR) consulting projects for the pharmaceutical industry for 20 years. His experience includes trial analyses, economic modeling, and indirect treatment comparisons for ​HTA submissions.

In 2015, using his experience in HEOR, Bart co-founded Ingress Health, which merged with Cytel in 2020. He is passionate about developing or extending methodologies such as Bayesian survival network meta-analyses, developing tumor agnostic models and models for early/adjuvant oncology therapies.

Bart has a PhD in health economics from the University of Groningen, which focused on modeling chronic diseases for reimbursement purposes.